Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer
Authors:
- 15 March 2015
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 75 (5) , 993-1004
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Current opinion on optimal treatment for colorectal cancerExpert Review of Anticancer Therapy, 2013
- Cancer statistics, 2013CA: A Cancer Journal for Clinicians, 2013
- ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingAnnals of Oncology, 2012
- An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal CancerClinical Colorectal Cancer, 2012
- Integration of Biologic Agents With Cytotoxic Chemotherapy in Metastatic Colorectal CancerClinical Colorectal Cancer, 2011
- A Decade of Advances in Cytotoxic Chemotherapy for Metastatic Colorectal CancerClinical Colorectal Cancer, 2011
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumorsCancer Chemotherapy and Pharmacology, 2010
- Phase II Study of Safety and Efficacy of Motesanib in Patients With Progressive or Symptomatic, Advanced or Metastatic Medullary Thyroid CancerJournal of Clinical Oncology, 2009
- Motesanib Diphosphate in Progressive Differentiated Thyroid CancerNew England Journal of Medicine, 2008
- AMG 706, an Oral, Multikinase Inhibitor that Selectively Targets Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors, Potently Inhibits Angiogenesis and Induces Regression in Tumor XenograftsCancer Research, 2006